A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

TERMINATED

Status

538

Enrollment

INDUSTRY

Sponsor class

Stopped Considering the life-threatening risk posed by COVID-19 disease to a fragile population, the Sponsor concluded that the benefit of continuing the study does not outweigh the risk to the safety of patients \& site staffs.

Conditions

Breast Neoplasms

Interventions

DRUG: Herceptin (trastuzumab)
DRUG: SB3 (proposed trastuzumab biosimilar)

Sponsor

Samsung Bioepis Co., Ltd.